Schuler Education Foundation - 11 Feb 2020 Form 4 Insider Report for BIOLASE, INC (BIOLQ)

Role
10%+ Owner
Signature
/s/ Jack W. Schuler, President
Issuer symbol
BIOLQ
Transactions as of
11 Feb 2020
Net transactions value
-$1,841,263
Form type
4
Filing time
26 May 2023, 13:13:30 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIOL Common Stock Purchase $797,838 +1,307,931 +14% $0.6100* 10,936,444 11 Feb 2020 Direct F1
transaction BIOL Common Stock Sale $1,016,207 -1,847,649 -17% $0.5500* 9,088,795 08 Jun 2020 Direct F1, F2
transaction BIOL Common Stock Sale $1,154,282 -2,137,559 -24% $0.5400* 6,951,236 09 Jun 2020 Direct F1, F3
transaction BIOL Common Stock Sale $953,610 -1,733,836 -25% $0.5500* 5,217,400 10 Jun 2020 Direct F1, F4
transaction BIOL Common Stock Conversion of derivative security $1,498,000 +3,745,000 +72% $0.4000* 8,962,400 28 Jul 2020 Direct F1
transaction BIOL Common Stock Sale $21,330 -71,100 -0.79% $0.3000 8,891,300 24 Nov 2020 Direct F1
transaction BIOL Common Stock Sale $58,887 -203,057 -2.3% $0.2900 8,688,243 25 Nov 2020 Direct F1
transaction BIOL Common Stock Sale $334,500 -1,115,000 -13% $0.3000 7,573,243 30 Nov 2020 Direct F1
transaction BIOL Common Stock Sale $360,000 -1,200,000 -16% $0.3000 6,373,243 04 Dec 2020 Direct F1
transaction BIOL Common Stock Sale $25,361 -90,575 -1.4% $0.2800 6,282,668 16 Dec 2020 Direct F1
transaction BIOL Common Stock Sale $160,348 -572,671 -9.1% $0.2800 5,709,997 17 Dec 2020 Direct F1
transaction BIOL Common Stock Sale $52,577 -187,774 -3.3% $0.2800 5,522,223 18 Dec 2020 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIOL Series F Convertible Preferred Stock Award +1,498 1,498 22 Jul 2020 Common Stock 3,745,000 $0.4000 Direct F1, F5, F6
transaction BIOL Warrants Award +3,745,000 3,745,000 22 Jul 2020 Common Stock 3,745,000 $0.4000 Direct F1, F5
transaction BIOL Series F Convertible Preferred Stock Conversion of derivative security -1,498 -100% 0 28 Jul 2020 Common Stock 3,745,000 $0.4000 Direct F1, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Schuler Education Foundation is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This late filing is due to inadvertent administrative error.
F2 The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5399 and $0.5643, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3 The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5430 and $0.5601, inclusive.
F4 The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5485 and $0.5656, inclusive.
F5 In connection with a public offering by the Issuer, on July 22, 2020, the Reporting Person acquired (i) 1,498 shares of Series F Convertible Preferred Stock, each of which is convertible into 2,500 shares of Common Stock, for a total of up to 3,745,000 shares of Common Stock, and (ii) 3,745,000 Warrants, each of which is exercisable to purchase one share of Common Stock, for a total of up to 3,745,000 shares of Common Stock, for an aggregate purchase price of $1,500,000.
F6 Each share of Series F Convertible Preferred Stock is convertible at the Issuer's option at any time on or after July 22, 2021 or at the option of the Reporting Person at any time.
F7 On July 28, 2020, the Reporting Person converted 1,498 shares of Series F Convertible Preferred Stock into 3,745,000 shares of Common Stock.